Discordant High Activated Partial Thromboplastin Time Relative to Anti-Xa Values in Hospitalized Patients is an Independent Risk Factor for Increased 30-day Mortality

Abstract

Background The activated partial thromboplastin time (aPTT) and anti-factor-Xa levels (anti-Xa) are both used to monitor patients on unfractionated heparin. Our previous study demonstrated that patients with discordant high aPTT relative to anti-Xa had higher rates of mortality and bleeding events.

Objective To determine if underlying patient characteristics drive both discordance and adverse outcomes or if discordance is an independent risk factor to adverse outcomes.

Methods We analyzed all patients hospitalized at the Stanford Hospital between January 2011 and December 2019 who had simultaneous aPTT and anti-Xa levels performed. From the electronic medical record, we extracted and analyzed 51 patient features including baseline coagulation laboratory results, demographics, values of other common laboratories (basic metabolic panel, complete blood count, etc.), diagnostic procedures, medications, and death.

Results A total of 17,728 patients had 78,701 paired aPTT and anti-Xa levels. Patients with discordant aPTT and anti-Xa where aPTT (seconds) was elevated beyond the expected therapeutic range had a higher 30-day mortality (odds ratio [OR]: 2.16, 95% confidence interval [CI]: 1.78–2.63, p < 0.001). Sectioning the patients based on the degree of discordance and whether aPTT or anti-Xa were signaling excess anticoagulation, we found those with an elevated aPTT discordant to their anti-Xa level had the highest odds of death (OR: 2.46, 95% CI: 1.99–3.10) compared with the concordant group. This finding was still present after controlling for patient comorbidity and other laboratory results at hospital admission.

Conclusion After controlling for patient features strongly associated with increased mortality in heparinized patients, we identified that the discordant pattern of high aPTT to anti-Xa served as an independent predictor of 30-day all-cause mortality, with a higher degree of discordance associated with increased odds of 30-day mortality.

Keywords

activated partial thromboplastin time - anti-factor Xa - concordance - discordant - unfractionated heparin

Publikationsverlauf

Artikel online veröffentlicht:
27. August 2024

• References

• 1 Devreese KM, Verfaillie CJ, De Bisschop F, Delanghe JR. Interference of C-reactive protein with clotting times. Clin Chem Lab Med 2015; 53 (05) e141-e145
• 2 Wu XY, Yin YF, Teng JL, Zhang LW, Yang CD. IgMk paraprotein from gammopathy patient can bind to cardiolipin and interfere with coagulation assay: a case report. BMC Immunol 2017; 18 (01) 32
• 3 Cooper MR, Cohen HJ, Huntley CC, Waite BM, Spees L, Spurr CL. A monoclonal IgM with antibodylike specificity for phospholipids in a patient with lymphoma. Blood 1974; 43 (04) 493-504
• 4 Olson JD, Arkin CF, Brandt JT. et al. College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: laboratory monitoring of unfractionated heparin therapy. Arch Pathol Lab Med 1998; 122 (09) 782-798
• 5 Hirsh J, Guyatt G, Lewis SZ. Reflecting on eight editions of the American College of Chest Physicians antithrombotic guidelines. Chest 2008; 133 (06) 1293-1295
• 6 Vandiver JW, Vondracek TG. Antifactor Xa levels versus activated partial thromboplastin time for monitoring unfractionated heparin. Pharmacotherapy 2012; 32 (06) 546-558
• 7 Cuker A, Ptashkin B, Konkle BA. et al. Interlaboratory agreement in the monitoring of unfractionated heparin using the anti-factor Xa-correlated activated partial thromboplastin time. J Thromb Haemost 2009; 7 (01) 80-86
• 8 Hutt Centeno E, Militello M, Gomes MP. Anti-Xa assays: what is their role today in antithrombotic therapy?. Cleve Clin J Med 2019; 86 (06) 417-425
• 9 Price EA, Jin J, Nguyen HM, Krishnan G, Bowen R, Zehnder JL. Discordant aPTT and anti-Xa values and outcomes in hospitalized patients treated with intravenous unfractionated heparin. Ann Pharmacother 2013; 47 (02) 151-158
• 10 Takemoto CM, Streiff MB, Shermock KM. et al. Activated partial thromboplastin time and anti-Xa measurements in heparin monitoring: biochemical basis for discordance. Am J Clin Pathol 2013; 139 (04) 450-456
• 11 Ratano D, Alberio L, Delodder F, Faouzi M, Berger MM. Agreement between activated partial thromboplastin time and anti-Xa activity in critically ill patients receiving therapeutic unfractionated heparin. Thromb Res 2019; 175: 53-58
• 12 Aubron C, Chapalain X, Bailey M. et al. Anti-factor-Xa and activated partial thromboplastin time concordance and outcomes in adults undergoing extracorporeal membrane oxygenation: a secondary analysis of the pilot low-dose heparin in critically ill patients undergoing extracorporeal membrane oxygenation randomized trial. Crit Care Explor 2023; 5 (11) e0999
• 13 Faust AC, Kanyer D, Wittkowsky AK. Managing transitions from oral factor Xa inhibitors to unfractionated heparin infusions. Am J Health Syst Pharm 2016; 73 (24) 2037-2041
• 14 Taylor CT, Petros WP, Ortel TL. Two instruments to determine activated partial thromboplastin time: implications for heparin monitoring. Pharmacotherapy 1999; 19 (04) 383-387
• 15 Kovacs MJ, Keeney M, MacKinnon K, Boyle E. Three different chromogenic methods do not give equivalent anti-Xa levels for patients on therapeutic low molecular weight heparin (dalteparin) or unfractionated heparin. Clin Lab Haematol 1999; 21 (01) 55-60
• 16 Kitchen S. Problems in laboratory monitoring of heparin dosage. Br J Haematol 2000; 111 (02) 397-406